文献速递肝病

直接抗病毒药物时代,丙型肝炎因临床改善而退出肝移植等待名单仍不常见

In the Era of Direct-Acting Antivirals, Liver Transplant Delisting Due to Clinical Improvement for Hepatitis C Remains Infrequent.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-09-21

该研究基于美国国家数据回顾性分析2005年至2018年等待肝移植的成人患者,比较直接抗病毒药物(DAA)时代前后丙型肝炎(HCV)患者的等待名单动态。结果显示DAA时代HCV患者 listing 率下降,因临床改善退出等待名单仍不常见(2013-2017年6.1%),且许多退出者仍有腹水和脑病。

要点

  • DAA时代HCV患者肝移植等待名单登记率下降,尤其MELD评分≥15和≥30者。
  • 因临床改善退出等待名单的比例仍低:2013-2017年6.1%,2009-2012年5.2%,2005-2008年4%(p < .001)。
  • 退出时许多患者仍有腹水(46.5%)和脑病(30.5%)。

核心结论

  • DAA时代失代偿期HCV肝硬化患者等待名单登记率下降,因临床改善退出等待名单有所增加但仍不常见,许多患者仍有显著疾病负担。

研究设计与样本

  • 回顾性队列研究,使用美国国家数据,纳入2005年1月1日至2018年12月31日等待单独肝移植的成人患者,DAA后时代定义为2013年1月1日之后的登记。

主要发现

  • DAA时代HCV患者总体登记率下降,尤其MELD评分≥15和≥30者。
  • 登记时难治性腹水和严重脑病的比例增加。
  • 因临床改善退出等待名单的比例:2013-2017年6.1%,2009-2012年5.2%,2005-2008年4%(p < .001)。
  • 退出等待名单时,46.5%有腹水,30.5%有脑病。
  • DAA后时代HCV患者等待名单恢复更频繁(校正SHR 1.78 vs DAA前,95% CI:1.58-2.02;p < .001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND / AIMS: Studies have suggested marked increases in transplant delisting due to clinical improvement for patients with hepatitis C virus (HCV) associated cirrhosis in the era of direct acting antivirals (DAAs). This study provides a 'real world' assessment of waitlist dynamics for HCV transplant candidates in the current era. METHODS: This was a retrospective cohort study of adults waitlisted for liver transplant (LT) alone between 1/1/2005-12/31/2018 using national US data. The post-DAA era included all listings occurring after 1/1/2013. Temporal trends in waitlisting, patient characteristics and outcomes with decompensated cirrhosis were evaluated. Adjusted competing risks models assessed the interaction of DAA-era and HCV history on (i) waitlist mortality, and (ii) delisting due to clinical improvement. RESULTS: Overall listing rates for HCV patients have decreased in the DAA era and particularly with Model for End-stage Liver Disease score ≥15 and ≥30. Rates of refractory ascites and severe encephalopathy at listing have increased. Delisting due to clinical improvement remains low (6.1% for 2013-2017 versus 5.2% for 2009-2012 versus 4% for 2005-2008; p < .001) and, for many, ascites (46.5%) and encephalopathy (30.5%) persist at delisting. Waitlist recovery is more frequent for HCV patients post-DAA (adjusted SHR 1.78 vs pre-DAA, 95% CI: 1.58-2.02; p < .001), while improvements in waitlist mortality by era are similar to non-HCV candidates (adjusted SHR 0.74 [95% CI: 0.7-0.78; p < .001] and 0.77 [95% CI: 0.74-0.8; p < .001], respectively). CONCLUSION: Listing rates for decompensated HCV cirrhosis have decreased in the DAA era. Delisting of HCV patients for clinical improvement has increased, but remains infrequent and many continue to experience considerable morbidity.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Bittermann T, Reddy KR. In the Era of Direct-Acting Antivirals, Liver Transplant Delisting Due to Clinical Improvement for Hepatitis C Remains Infrequent. Clin Gastroenterol Hepatol. 2020. PMID: 32971230. doi:10.1016/j.cgh.2020.09.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。